First balance since the IPO: CureVac makes investors cheer – the share price jumped before the IPO | 11/30/20


For investors in the biotech company CureVac, things got exciting at the start of the week: the group opened its books for the first time since going public in September.

The Tübingen group CureVac has presented its figures for the third quarter and the first nine months of the current financial year.

Accordingly, the company listed on NASDAQ generated revenues of 5.16 million euros in the past quarter, after 1.096 million euros in the same quarter of the previous year. From January to September, CureVac had a total turnover of 42.83 million euros. In the same period a year earlier, sales were still 10.6 million euros.

The bottom line was that the company continued to write deep red figures: In the third quarter, the net loss was 36.83 million euros (previous year’s quarter: 18.36 million euros), and a net loss of 70.78 million euros over the entire nine-month period. For comparison: In the first three quarters of 2019, the net loss was 63.88 million euros.

CureVac shares temporarily gain 6.97 percent to 91.99 US dollars in pre-market trading on NASDAQ. editors

Source link


Please enter your comment!
Please enter your name here